Data on the parasitoid complexes of Metallus pumilus (Hymenoptera: Tenthredinidae) and Emmetia heinemanni (Lepidoptera: Tischeriidae) mining leaves of Rubus sp.

251 Rubus leaves mined by three species of leaf miners, Metallus pumilus (Klug, 1816), Emmetia heinemanni (Wocke, 1871) and Ectoedemia rubivora (Wocke, 1860), were collected between 2011 and 2014 in order to rear out their parasitoids. No parasitoids have been reared out from Ectoedemia rubivora, but we have identifi ed 3 parasitoid species from Emmetia heinemanni and 5 species from Metallus pumilus. With 2 tables

Monitoring of the Leafminer Leucoptera scitella Zell (Lepidoptera: Lyonetidae) by Pheromone Traps in Bulgaria

Three-years monitoring (1996 –1998)of the leafminer moth Leucoptera scitella Zell was organi- zed in the apple orchard of the Fruit-Growing Institute,Plovdiv,Bulgaria.Sex pheromone traps with Hunga- rian caps (Plant Protection Institute,Hungarian Academy of Sciences)were used for first time in this country. As a result,three full generation of the pests were established in all three years and a partial one in 1996 and 1998.The beginning and the end of the first generation were also well defined by the catches in the pheromone traps.However,an overlap of the second and the third on the one hand and the third and the fourth on the other,was observed in all three years.The time of the first catches from the first generation varied from April 9 to April 22.The second and third generation began in the second decade of June and second decade of July,respectively.Chemical treatments seem to have no significant effect on the catches in the pheromone traps

Screening some Common Molecular Markers and a Desaturase Marker, Linked to Sex Pheromone Biosynthesis, in Three Z-Strain and an E-Strain Populations of the European Corn Borer, Ostrinia nubilalis, Occurring in Central Europe

The European corn borer moth, (ECB), Ostrinia nubilalis (Lepidoptera: Crambidae, Pyraustinae) is one of the most destructive pests of maize worldwide. ECB has two pheromone-strains, separated by specific ratios of isomers of E- and Z11-tetradecenyl acetates (E11- and Z11-14Ac), but appearing morphologically identical. Accordingly, E- and Z-ECB pheromone traps are available for the respective populations for practical monitoring of the flight, however, traps for Z-strain are unreliable for practical usage in some parts of Central-Europe. E- and Z-ECB populations occur in sympatry in some areas, while in allelopatry in other areas. Determining the strains before the flight of adults, when difference in the composition of their respective pheromones is manifested, would be of practical interest for early warning. In addition to the known fatty-acyl-reductase (FAR) marker, further markers would allow more comprehensive studies. We screened the following common markers for mitochondrial and nuclear DNA regions: partial cytochrome c oxidase I (COI), cytochrome B (CytB), the second spacer of the internal transcribed spacer (ITS2), Elongation factor 1a (EF1a) and actin gene (Act). In addition, a marker of the Δ11-desaturase gene (11desat), linked to biosynthesis of female-produced sex pheromone, was also included, because we reported earlier a differential expression for this site. Three Z-ECB populations locating at distant sites within Hungary, an area where only Z-strain occurs, and an E-ECB population in Slovenia, known as the closest-occurring E-strain, were included into the study. Separate laboratory colonies were established from each population, and F1 generations were sampled to verify the identity of pheromone strains, by analysing the composition of sex pheromone by gas chromatography linked to an electroantennographic detector (GC-EAD). Molecular studies were conducted using specimens taken from the F2 generations. Results of genetic studies showed that there were no differences between the Z and E populations for the common markers. In contrast to this, several nucleic acid changes (11 nt in 4 positions) were found between the three Z-populations (Hungary) and the E-population (Slovenia) in the desaturase marker. Further study is required to reveal whether the differences found in this study are consistent across E-populations, thus making these markers suitable for diagnostic purposes

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

BACKGROUND: -Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. METHODS AND RESULTS: -We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensinconverting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74-0.94; P=0.003) or an emergency department visit for worsening heart failure (hazard ratio, 0.66; 95% confidence interval, 0.52-0.85; P=0.001). The patients in the LCZ696 group had 23% fewer hospitalizations for worsening heart failure (851 versus 1079; P<0.001) and were less likely to require intensive care (768 versus 879; 18% rate reduction, P=0.005), to receive intravenous positive inotropic agents (31% risk reduction, P<0.001), and to have implantation of a heart failure device or cardiac transplantation (22% risk reduction, P=0.07). The reduction in heart failure hospitalization with LCZ696 was evident within the first 30 days after randomization. Worsening of symptom scores in surviving patients was consistently more common in the enalapril group. LCZ696 led to an early and sustained reduction in biomarkers of myocardial wall stress and injury (N-terminal pro-Btype natriuretic peptide and troponin) versus enalapril. CONCLUSIONS: -Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotensin-converting enzyme inhibition. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

BACKGROUND: The prevalence of pre-diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known. We investigated these in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. METHODS AND RESULTS: We examined clinical outcomes in 8399 patients with heart failure and reduced ejection fraction according to history of diabetes mellitus and glycemic status (baseline hemoglobin A1c [HbA1c]: /=6.5% [>/=48 mmol/mol; diabetes mellitus]), in Cox regression models adjusted for known predictors of poor outcome. Patients with a history of diabetes mellitus (n=2907 [35%]) had a higher risk of the primary composite outcome of heart failure hospitalization or cardiovascular mortality compared with those without a history of diabetes mellitus: adjusted hazard ratio, 1.38; 95% confidence interval, 1.25 to 1.52; P6.5%) and known diabetes mellitus compared with those with HbA1c<6.0% was 1.39 (1.17-1.64); P<0.001 and 1.64 (1.43-1.87); P<0.001, respectively. Patients with pre-diabetes mellitus were also at higher risk (hazard ratio, 1.27 [1.10-1.47]; P<0.001) compared with those with HbA1c<6.0%. The benefit of LCZ696 (sacubitril/valsartan) compared with enalapril was consistent across the range of HbA1c in the trial. CONCLUSIONS: In patients with heart failure and reduced ejection fraction, dysglycemia is common and pre-diabetes mellitus is associated with a higher risk of adverse cardiovascular outcomes (compared with patients with no diabetes mellitus and HbA1c <6.0%). LCZ696 was beneficial compared with enalapril, irrespective of glycemic status. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255

Identification of female sex pheromone for monitoring the barred tooth striped moth, trichopteryx polycommata, a priority conservation species

Pheromone-baited traps can be excellent tools for sensitive detection of insects of conservation concern. Here, identification of the sex pheromone of Trichopteryx polycommata (Denis & Schiffermüller, 1775), an under-recorded UK priority species, is reported. In analyses of extracts of the pheromone glands of female T. polycommata by gas chromatography coupled to electroantennographic recording from the antenna of a male moth, a single active component was detected. This was identified as (Z,Z)-6,9-nonadecadiene (Z,Z6,9-19:H) by comparison of its mass spectrum and retention times with those of the synthetic standard. In a pilot field trial in Kent, UK, T. polycommata males were caught in pheromone traps baited with lures loaded with 1 mg and 2 mg (Z,Z)-6,9-19:H. Optimum lure loading was identified in a further five trials in Kent, Sussex and Lancashire where lures of 0, 0.001, 0.01, 0.1, 1, 2, 5 and 10 mg loadings were tested. Traps baited with 1 to 10 mg of ZZ6,9-19:H caught significantly more T. polycommata than traps baited with 0 mg and 0.001 mg. In a pilot survey of T. polycommata using pheromone lures around Morecambe Bay, UK, T. polycommata males were captured at 122 new sites within the three counties where trials took place, demonstrating the potential of pheromone monitoring to increase knowledge of abundance, distribution and ecology of this elusive species

Pseudouridylation defect due to DKC1 and NOP10 mutations causes nephrotic syndrome with cataracts, hearing impairment, and enterocolitis

Research UK Innovation and Project; Cancer Research U